OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A.

CNPJ/ME No. 20.258.278/0001-70

NIRE 35.300.465.415

MATERIAL FACT

OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A. ("**Company**"), pursuant to the applicable law, hereby informs its shareholders and the market in general that the National Health Surveillance Agency (*Agência Nacional de Vigilância Sanitária - ANVISA*) published, on December 26, 2019, the Normative Instruction No. 51, of December 19, 2019 ("**IN51**"), establishing a list of maximum residue limits (MRL), acceptable daily intake (ADI) and acute reference dose (ARfD) for active pharmaceutical ingredients (API) of veterinary medicines in foods of animal origin.

The IN51 provides that for veterinary medication registered in Brazil until the date of its publication and that contains in its formulation an API without the MRL indicated in IN51, a limit not exceeding 10 micrograms per kilo in the analyzed matrix will be tolerated, during the adjustment period provided for in RDC Resolution No. 328, of December 19, 2019, also published on December 26, 2019 ("**RDC328**").

In addition to IN51, RDC328 provides for the assessment of risks of veterinary medication to human health and methods of analysis for the purposes of compliance assessment, establishing a 5-year period for the presentation of documentation that supports the establishment of new ADI and MRL, extendable for a maximum period of two (2) years, when the need to conclude scientific studies is demonstrated.

In this context, the Company is currently evaluating the economic impacts of an eventual restriction for sale of some of its products that might be impacted by regulation above, as well as taking the following actions:

- Immediate steps to carry out technical tests in order to readjust the grace periods for the impacted products, so that they meet the maximum residue tolerance in the matrices not exceeding 10 micrograms per kilo.

- Evaluation of the development of scientific studies that enable the presentation of documentation that supports the establishment of ADI and MRL, for the adequacy of the impacted products within the 5-year period, provided for in Resolution RDC No. 328.

- In addition, the Company continuously seeks alternative pharmaceutical ingredients for the development of new products and updating its portfolio.

The Company will maintain its shareholders and the market in general informed of any relevant developments regarding the matter of this Material Fact.

Cravinhos, January 20, 2020.

Kleber Cesar Silveira Gomes

Chief Financial and Investor Relations Officer